RetinaLyze System A/S unveils AI to aid in the early detection of glaucoma

News
Article

As much as 96% of customers and 60% of patients can get their results in less than a minute with Retinalyze, according to the company.

Eye undergoing retinal scan Image credit: AdobeStock/АннаКовальчук

Image credit: AdobeStock/АннаКовальчук

RetinaLyze System A/S has unveiled an advanced glaucoma progression artificial intelligence (AI), which works to offer a stable and consistent method for tracking glaucoma over time.1 The Glaucoma Index of Progression (GIP) provides the ability to detect glaucoma early by measuring subtle changes in disease progression and status, according to a news release.

GIP also features the ability to compare changes in both eyes simultaneously, allowing eye care providers to examine GIP indices along the estimated areas of the optic cup and rim sectors. This can then facilitate a better understanding of the progression or regression affecting the optic nerve and surrounding structures in the eye.1

RetinaLyze is a screening software that utilizes an automated algorithm module to detect signs of eye disease by analyzing fundus images and OCT scans via pathology detection. It can be used as a clinical decision support system or as a screening tool in conjunction with a telemedicine module.2

According to RetinaLyze System A/S CCO Ganesh Ram, 96% of customers and 60% of patients can get their results in less than a minute, in addition to streamlining referral for patients.3 “By using the system, what you’re doing is you’re lowering the risk of referring erroneous results, so you’re not forwarding too many false positive to the local ophthalmologists,” he said in a presentation.

Additionally, larger optometric retailers can integrate the AI tool in about 6 months, with smaller private practice able to get RetinaLyze running in a week.3

Free trials of the AI tool are available here.

References:
  1. RetinaLyze unveils advanced glaucoma progression AI with Glaucoma Index of Progression (GIP). News release. RetinaLyze. October 10, 2024. Accessed October 15, 2024. https://www.retinalyze.com/post/retinalyze-unveils-advanced-glaucoma-progression-ai-with-glaucoma-index-of-progression-gip?_gl=1*1wcxt36*_up*MQ..*_ga*MTA4MTcwMzAwMy4xNzI4OTk3OTY0*_ga_BF9TDN20MG*MTcyODk5Nzk2NC4xLjEuMTcyODk5Nzk4MS4wLjAuMA..*_ga_53ZNZ9GL12*MTcyODk5Nzk2NC4xLjEuMTcyODk5Nzk4MS4wLjAuMTc5OTQ4NDE1Mw..
  2. Time-saving eye screenings with AI. RetinaLyze. Accessed October 15, 2024. https://www.retinalyze.com/?_gl=1*1f2hhn0*_up*MQ..*_ga*NjAzMzI0NDYzLjE3MjkwMDQxNzM.*_ga_BF9TDN20MG*MTcyOTAwNDE3Mi4xLjAuMTcyOTAwNDE3Mi4wLjAuMA..*_ga_53ZNZ9GL12*MTcyOTAwNDE3Mi4xLjAuMTcyOTAwNDE3Mi4wLjAuOTEyOTk0Mjk4
  3. RetinaLyze System A/S. RetinaLyze Distributor Presentation – June 2024. Accessed October 15, 2024. https://www.youtube.com/watch?v=ypxSQEFQD3o
Recent Videos
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
A. Paul Chous, MA, OD, FAAO, details a presentation on this year's updates on diabetes given at this year's Academy meeting
© 2024 MJH Life Sciences

All rights reserved.